Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cardiovascular disease mortality risk

The a-tocopherol, P-carotene (ATBC) Cancer Prevention study was a randomised-controlled trial that tested the effects of daily doses of either 50 mg (50 lU) vitamin E (all-racemic a-tocopherol acetate), or 20 mg of P-carotene, or both with that of a placebo, in a population of more than 29,000 male smokers for 5-8 years. No reduction in lung cancer or major coronary events was observed with any of the treatments. What was more startling was the unexpected increases in risk of death from lung cancer and ischemic heart disease with P-carotene supplementation (ATBC Cancer Prevention Study Group, 1994). Increases in the risk of both lung cancer and cardiovascular disease mortality were also observed in the P-carotene and Retinol Efficacy Trial (CARET), which tested the effects of combined treatment with 30 mg/d P-carotene and retinyl pahnitate (25,000 lU/d) in 18,000 men and women with a history of cigarette smoking or occupational exposure to asbestos (Hennekens et al, 1996). [Pg.33]

Cardiovascular diseases remain the main cause of death in developed countries. Studies relating the intake of dietary flavonoids to risk of cardiovascular disease (mortality from coronary heart disease, incidence of... [Pg.566]

Cardiovascular disease mortality, accounting for 50% of all deaths in ESRD, is defined by death caused by arrhythmias, cardiomyopathy, cardiac arrest, myocardial infarction, atherosclerotic heart disease, and pulmonary edema. Patients with ESRD should be considered in the highest risk group for subsequent cardiovascular events. Among dialysis patients, the prevalence of congestive heart failure is approximately 40%. Both coronary artery disease and LVH are risk factors for the development of heart failure. In practice, it is difficult to determine whether cardiac failure reflects left ventricular dysfunction or extracellular fluid volume overload. [Pg.1723]

Monitoring for efficacy, adverse events, and adherence to therapy is key to achieving the long-term goals of reducing the risk of morbidity and mortality associated with cardiovascular disease. [Pg.30]

Cardiovascular disease has been identified as one of the leading causes of death in organ transplant recipients.55 Posttransplant hypertension (HTN) is associated with an increase in cardiac morbidity and patient mortality in all transplant patients and is also an independent risk factor for chronic allograft dysfunction and loss.56 Based on all the available posttransplant morbidity and mortality data, it is imperative that posttransplant HTN be identified and managed appropriately. [Pg.846]

Hyperlipidemia is seen in up to 60% of heart, lung, and renal transplant patients and greater than 30% of liver transplant patients.64 66 As a result of elevated cholesterol levels, transplant recipients are not only at an increased risk of atherosclerotic events, but emerging evidence also shows an association between hyperlipidemia and allograft vasculopathy.66 Hyperlipidemia, along with other types of cardiovascular disease, is now one of the primary causes of morbidity and mortality in long-term transplant survivors.67... [Pg.848]

Heidemann C, Schulza MB, Franco OH, Van Dam RM, Mantzoros CS and Hu FB. 2008. Dietary patterns and risk of mortality from cardiovascular disease, cancer and all causes in a prospective cohort of women. Circulation 118 230-237. [Pg.232]

Premature ovarian failure is a condition characterized by sex-steroid deficiency, amenorrhea, and infertility in women younger than 40 years of age. It affects 1% of women. Premature ovarian failure is associated with a significantly higher risk for osteoporosis and cardiovascular disease and increased mortality. [Pg.364]

Obesity is associated with serious health risks and increased mortality. Central obesity reflects high levels of intraabdominal or visceral fat that is associated with the development of hypertension, dyslipidemia, type 2 diabetes, and cardiovascular disease. [Pg.677]

The health effects of particulate matter (a complex mixture of solids and liquids) emissions are not yet well understood but are recognized as major contributors to health problems. Biological activity of particulate matter may be related to particle sizes and/or particle composition. Furthermore, it has generally been concluded that exposure to particulate matter may cause increased morbidity and mortality, such as from cardiovascular disease. Long-term exposure to particulate emissions is also associated with a small increase in the relative risk of lung cancer. [Pg.245]

As noted above, obesity is a health problem. It is associated with both elevated mortality and morbidity. More specifically, obesity is a risk factor for cardiovascular disease, including heart attack and stroke, and for high blood pressure (hypertension), diabetes, and hyperlipidemia (elevated levels of lipids in the blood, a risk factor for atherosclerosis and its sequelae), and for cancer. [Pg.239]

A cohort study of 5668 NG-exposed workers found an increased standardized mortality ratio for deaths from ischemic heart disease. The increase was more pronounced for those with 10 or more years of exposure and was statistically significant for the 40- to 49-year age group, whereas a deficit of cardiovascular mortality had been anticipated because of preplacement and annual medical examinations designed to exclude persons with cardiovascular abnormalities. These results were confirmed in a retrospective cohort mortality study that found a significant excess of ischemic heart disease mortality among workers actively exposed to NG and under the age of 45. ° (Note this study failed to detect a chronic cardiovascular effect as excess risk was only associated with workers actively exposed to NG.)... [Pg.528]

Lowering cholesterol levels can arrest or reverse atherosclerosis in all vascular beds and can significantly decrease the morbidity and mortality associated with atherosclerosis. Each 10% reduction in cholesterol levels is associated with an approximately 20% to 30% reduction in the incidence of coronary heart disease. Hyperlipidemia, particularly elevated serum cholesterol and low density lipoprotein (LDL) levels, is a risk factor in the development of atherosclerotic cardiovascular disease. [Pg.599]

GH synthesis and secretion does not disappear when linear growth is complete. In fact isolation of hGH from cadaver pituitary glands would not have been possible if it did. Physicians caring for adult patients with pituitary disease began to realize that even with optimum replacement of other hormones, patients who acquired GH deficiency in adulthood complained bitterly about diminished quality of life. Studies from Europe also documented increased cardiovascular morbidity and mortality in these patients [13], Because it was no longer necessary to conserve scarce supplies of hGH for use in children, physicians were able to study GH effects in adults with growth hormone deficiency. These studies have shown that GH improves body composition (decreases fat mass and increases lean body mass) and decreases risk factors for cardiovascular disease [14]. [Pg.213]

Virtanen, J. K., Voutilainen, S., Rissanen, T. H., Mursu, J., Tuomainen, T. P., Korhonen, M. J., Valkonen, V. P., Seppanen, K., Laukkanen, J. A., and Salonen, J. T. (2005). Mercury, fish oils, and risk of acute coronary events and cardiovascular disease, coronary heart disease, and all-cause mortality in men in eastern Finland. Arterioscler. Thromb. Vase. Biol. 25, 228-233. [Pg.222]

Tea is another important dietary source for flavonoids, In fact, about half of the flavonoid intake in western populations is derived from black tea. Tea was the major source of flavonoids in the Dutch [6,13] and Welsh studies [17]. Only a small number of studies investigated the association between tea consumption and cardiovascular disease risk. No association between tea consumption and cardiovascular disease risk were reported in Scottish men and women [28] and in U.S. men in the Health Professionals follow-up study [29]. However, in a Norwegian population an inverse association was reported between tea intake, serum cholesterol, and mortality from coronary heart disease [30]. Several studies reported that tea consumption did not affect plasma antioxidant activity [31] and hemostatic factors [32]. However, a recent prospective study (the Rotterdam study) of 3,454 men and women 55 years and older followed for 2 to 3 years, showed a significant, inverse association of tea intake with severe (> 5 cm the length of the calcified area) aortic atherosclerosis. Odds ratios decreased approximately 70 % for drinking more than 500 mL/day (4 cups per day). The associations were stronger in women than in men. However, the risk reductions for moderate and mild atherosclerosis were only weak or absent [33]. [Pg.570]

Wollin and Jones (2001) investigated the effects and mechanisms of action of consumption of red wine compared to other alcoholic beverages on the risk of cardiovascular disease. Of particular interest was the form and quantity of alcohol consumed. The relationship between alcohol consumption and mortality is supported by epidemiologic studies suggesting that different forms of alcohol alter the relative risk for mortality. Evidence... [Pg.239]

Statins are helpful in decreasing morbidity and mortality in people with high cholesterol, as well as individuals who have normal cholesterol but other risk factors for cardiovascular disease.66 It is estimated that these drugs decrease the risk of a major cardiac event by approximately 30 to 35 percent, although the benefits depend on the extent that cholesterol is reduced and the influence of other risk factors.91,95,126 Nonetheless, statins are now regarded as a mainstay in treating cardiovascular disease, and efforts are underway to expand the use of these medications and to explore the... [Pg.358]

In view of the perceived benefit of aspirin in the secondary prevention of stroke and myocardial infarction, two large trials involving physicians as subjects were initiated to study the effect of aspirin in the primary prevention of arterial thrombosis. In the American study, 22,000 volunteers (age 40 to 84 years) were randomly assigned to take 325 mg of aspirin every other day or placebo. The trial was halted early, after a mean follow-up of 5 years, when a 45% reduction in the incidence of myocardial infarction and a 72% reduction in the incidence of fatal myocardial infarction were noted with aspirin treatment. However, total mortality was reduced only 4% in the aspirin group, a difference that was not statistically significant, and there was a trend for a greater risk of hemorrhagic stroke with aspirin. Thus, the prophylactic use of aspirin in an apparently healthy population is not recommended at this time, unless there are risk factors for cardiovascular disease. [Pg.413]

The Multiple Risk Factor Intervention Trial (Dolecek, 1992) included over 12,000 men over an 8-year period. The results showed that higher ALA intakes were associated with lower risks of death due to coronary heart disease and cardiovascular disease. Furthermore, a 28% reduction in risk of stroke was associated with a 0.06% increase in the ALA content of serum phospholipids (Simon et al., 1995). Other studies have since supported the association between ALA and reduction in stroke risk (Leng et al., 1999 Vartiainen et al., 1994). Vartiainen et al. (1994) followed a Finnish population of approximately 28,000 men and women over 20 years and found that a 60% reduction in mortality from stroke was associated with increased ALA consumption. In a study involving approximately 1,100 subjects, individuals suffering a stroke had significantly lower ALA concentrations in the red blood cell (Leng et al., 1999). [Pg.31]

Hypertension is the most common cardiovascular disease. Thus, the third National Health and Nutrition Examination Survey (NHANES III), conducted from 1992 to 1994, found that 27% of the USA adult population had hypertension. The prevalence varies with age, race, education, and many other variables. Sustained arterial hypertension damages blood vessels in kidney, heart, and brain and leads to an increased incidence of renal failure, coronary disease, cardiac failure, and stroke. Effective pharmacologic lowering of blood pressure has been shown to prevent damage to blood vessels and to substantially reduce morbidity and mortality rates. Many effective drugs are available. Knowledge of their antihypertensive mechanisms and sites of action allows accurate prediction of efficacy and toxicity. As a result, rational use of these agents, alone or in combination, can lower blood pressure with minimal risk of serious toxicity in most patients. [Pg.225]

In case LDL oxidation is considered as an important risk factor, the dosage of vitamin E may be important to determine a clinical effect. However, with respect to inhibition of protein kinase-C and the release of proinflammatory cytokines the intracellular transfer of RRRT (natural vitamin E) by the tocopherol-associated protein may be a crucial point. Consequently, natural vitamin E is considered more effective than the synthetic one. Since the activity on LDL oxidation was pointed out as important for the prevention of cardiovascular disease, most of the long-term trials with vitamin E were conducted at dosages >200 mg/day (about 200 lU/d). In a recent meta-analysis the association of plasma levels and mortality was studied in 1168 elderly European men and women (25). No association was found between the plasma concentration and all-cause or cause-specific mortality. [Pg.219]


See other pages where Cardiovascular disease mortality risk is mentioned: [Pg.388]    [Pg.428]    [Pg.123]    [Pg.252]    [Pg.144]    [Pg.170]    [Pg.275]    [Pg.15]    [Pg.49]    [Pg.374]    [Pg.353]    [Pg.235]    [Pg.177]    [Pg.116]    [Pg.462]    [Pg.444]    [Pg.381]    [Pg.221]    [Pg.280]    [Pg.368]    [Pg.224]    [Pg.630]    [Pg.201]    [Pg.262]    [Pg.100]    [Pg.85]    [Pg.49]    [Pg.52]    [Pg.292]   
See also in sourсe #XX -- [ Pg.160 ]




SEARCH



Cardiovascular disease

Cardiovascular disease mortality

Cardiovascular mortality

Cardiovascular risk

Mortality

© 2024 chempedia.info